Goserelin clinical trials
Goserelin is named as an intervention in 26 current clinical trials in our China, Taiwan, Mexico, Canada, Israel, USA, Italy, Germany, France, India, Spain, Portugal, Turkey, Brazil, South Korea, Sweden, Ireland, Belgium, Poland, Japan, Singapore, Australia, Egypt, Netherlands and Norway registers. 9 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is NRG Oncology (3). The most-studied condition is Breast Cancer. The EU clinical trials register (CTIS) separately lists 4 authorised or ongoing trials, 1 with a site in Ireland.
Where Goserelin is approved
All regulators →Of the three regulators tracked here, the first to approve Goserelin was the US, on 29 Dec 1989. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Goserelin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Goserelin works
All drug targets →- Gonadotropin-releasing hormone receptor agonist AgonistTarget: GNRHR gonadotropin releasing hormone receptor✓ In ChEMBL and the Guide to Pharmacology
- Lower urinary tract symptomPhase 3
- Prostate adenocarcinomaPhase 3
- Prostate cancerPhase 3
- Uterine corpus leiomyomaPhase 3
- AdenomyomaPhase 2/3
- AdenomyosisPhase 2/3
- CancerPhase 2/3
- Insulin resistancePhase 2
- Breast carcinomaPhase 2
- Estrogen-receptor positive breast cancerPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201247, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 3879, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Goserelin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 5 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Goserelin
- ATC code
- L02AE03
- ChEMBL
- CHEMBL1201247
- DrugBank
- DB00014
- PubChem CID
- 5311128
- CAS number
- 65807-02-5
- FDA UNII
- 0F65R8P09N
- Wikidata
- Q1992653
- Wikipedia
- Goserelin
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Goserelin
26 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Goserelin in the EU trials register (CTIS)
4 trials · 1 in IrelandAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Goserelin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
Goserelin across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
5 single-substance products containing Goserelin on the HPRA medicines list.
- Zoladex 3.6 mg implantAstraZeneca AB · PA1019/027/001 · Marketed
- Zoladex LA 10.8 mg implantAstraZeneca AB · PA1019/027/002 · Marketed
- Zoladex 3.6 mg implantIMED Healthcare Ltd., · PPA1463/125/001
- Zoladex LA 10.8 mg ImplantOriginalis B.V. · PPA2306/027/001
- Zoladex LA 10.8 mg implantIMED Healthcare Ltd., · PPA1463/125/002
Supply shortages
No entry for Goserelin in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Goserelin
33 conditionsAll 33 conditions
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 6 |
| Prostate Cancer | 4 |
| Breast Neoplasms | 2 |
| Metastatic Breast Cancer | 2 |
| Early Breast Cancer | 2 |
| HER2-negative Breast Cancer | 2 |
| Breast Neoplasm | 2 |
| Ovarian Insufficiency | 2 |
| Hormone Receptor Positive Tumor | 2 |
| Early-Stage Breast Carcinoma | 2 |
| Prostate Adenocarcinoma | 2 |
| Invasive Breast Cancer | 1 |
| Estrogen-receptor-positive Breast Cancer | 1 |
| Salivary Gland Carcinoma | 1 |
| Precision Therapy | 1 |
| Breast Tumors | 1 |
| Triple-Negative Breast Cancer (TNBC) | 1 |
| Allogeneic Haematopoietic Stem Cell Transplantation | 1 |
| Malignant Hematologic Disease | 1 |
| Autologous Hematopoietic Stem Cell Transplantation | 1 |
| Salivary Duct Carcinoma | 1 |
| Estrogen Receptor Positive Tumor | 1 |
| Stage III Prostate Cancer AJCC v8 | 1 |
| Stage IVA Prostate Cancer AJCC v8 | 1 |
| Stage I Prostate Adenocarcinoma AJCC v7 | 1 |
| Stage II Prostate Adenocarcinoma AJCC v7 | 1 |
| Stage III Prostate Adenocarcinoma AJCC v7 | 1 |
| Anatomic Stage III Breast Cancer AJCC v8 | 1 |
| Anatomic Stage IV Breast Cancer AJCC v8 | 1 |
| Breast Adenocarcinoma | 1 |
| HER2/Neu Negative | 1 |
| Premenopausal Breast Cancer | 1 |
| ER Positive Breast Cancer | 1 |
Sponsors
lead sponsor per trial+ 4 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Goserelin trials
How many clinical trials are testing Goserelin?
26 current trials in our China, Taiwan, Mexico, Canada, Israel, USA, Italy, Germany, France, India, Spain, Portugal, Turkey, Brazil, South Korea, Sweden, Ireland, Belgium, Poland, Japan, Singapore, Australia, Egypt, Netherlands and Norway registers name Goserelin (also registered as ICI-118630) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Goserelin trials recruiting patients?
Yes. 9 of the 26 trials are recruiting: 6 with sites in China, 3 with sites in Taiwan, 1 with sites in USA, 1 with sites in Italy, 1 with sites in Germany, 1 with sites in France, 1 with sites in Ireland, 1 with sites in Belgium and 1 with sites in Netherlands. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Goserelin clinical trials?
NRG Oncology (3), Novartis Pharmaceuticals (2), Fudan University (2) and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2), among 19 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Goserelin clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Goserelin licensed in Ireland?
Yes. The HPRA medicines list includes 5 single-substance products containing Goserelin, for example Zoladex 3.6 mg implant (AstraZeneca AB). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Goserelin shortage?
Not in the lists we track: Goserelin has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Goserelin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Goserelin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Goserelin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.